Skip to main content

Entresto (Sacubitril/​Valsartan) & Angioedema

Basic Details
Status
Complete
Last Updated
Wednesday, April 21, 2021
Original Posting Date
Health Outcome(s)
angioedema
Purpose
Drug and Outcome Analysis
Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
Yes
Analytic Code Link(s) (2)
Angioedema following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Result(s) (4)
Utilization of Sacubitril/Valsartan: A Descriptive Analysis Sacubitril/Valsartan, Angiotensin-Converting Enzyme (ACE) Inhibitors, and Other Angiotensin II Receptor Blockers (ARBs) Use in Patients with Heart Failure Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: A Propensity Score Analysis Angioedema Following Sacubitril/Valsartan Use in Patients with Heart Failure: An Updated Propensity Score Matched Analysis
Related Publication(s) and/or Presentation(s) (2)
Publication: Comparative Risk of Angioedema with Sacubitril-Valsartan Versus Renin-Angiotensin-Aldosterone Inhibitors Presentation: Utilization of Sacubitril/Valsartan in Real-World Settings